

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
9 February 2006 (09.02.2006)

PCT

(10) International Publication Number  
WO 2006/015049 A1

(51) International Patent Classification<sup>7</sup>: A61F 2/06

(21) International Application Number: PCT/US2005/026650

(22) International Filing Date: 27 July 2005 (27.07.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/591,950 28 July 2004 (28.07.2004) US

(71) Applicant (for all designated States except US): CORDIS CORPORATION [US/US]; 14201 NW 60TH Avenue, Miami Lakes, FL 33014 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MAJERCAK, David, C. [US/US]; 519 Madison Drive, Stewartsville, NJ 08886 (US). PARK, Jin, S. [US/US]; 300 Parsippany Road, Apt. #8H, Parsippany, NJ 07054 (US). SANCHEZ, Diana, M. [US/US]; 6 Franklin Court, Bernardsville, NJ 07924 (US).

(74) Agents: JOHNSON, Philip, S. et al.; Johnson & Johnson, 1 Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: REDUCED DEPLOYMENT FORCE DELIVERY DEVICE



(57) Abstract: A reduced deployment force delivery apparatus having an outer sheath with two layers that move relative to one another so as to reduce the deployment force necessary for deploying a stent, stent graft or other intraluminal device.

WO 2006/015049 A1

**REDUCED DEPLOYMENT FORCE DELIVERY DEVICE****Cross Reference to Related Applications**

This application claims the benefit of U.S. Provisional Patent Application Serial  
5 No. 60/591,950 filed July 28, 2004.

**BACKGROUND OF THE INVENTION****1. Field of the Invention**

10

The present invention relates to delivery devices, and more particularly, to reduced deployment force delivery devices for self-deploying intraluminal devices.

15

**2. Discussion of the Related Art**

An aneurysm is an abnormal dilation of a layer or layers of an arterial wall, usually caused by a systemic collagen synthetic or structural defect. An abdominal aortic aneurysm is an aneurysm in the abdominal portion of the aorta, 20 usually located in or near one or both of the two iliac arteries or near the renal arteries. The aneurysm often arises in the infrarenal portion of the diseased aorta, for example, below the kidneys. A thoracic aortic aneurysm is an aneurysm in the thoracic portion of the aorta. When left untreated, the aneurysm may rupture, usually causing rapid fatal hemorrhaging.

25

Aneurysms may be classified or typed by their position as well as by the number of aneurysms in a cluster. Typically, abdominal aortic aneurysms may be classified into five types. A Type I aneurysm is a single dilation located between the renal arteries and the iliac arteries. Typically, in a Type I aneurysm, 30 the aorta is healthy between the renal arteries and the aneurysm and between the aneurysm and the iliac arteries.

A Type II A aneurysm is a single dilation located between the renal arteries and the iliac arteries. In a Type II A aneurysm, the aorta is healthy between the renal arteries and the aneurysm, but not healthy between the aneurysm and the iliac arteries. In other words, the dilation extends to the aortic bifurcation. A Type II B aneurysm comprises three dilations. One dilation is located between the renal arteries and the iliac arteries. Like a Type II A aneurysm, the aorta is healthy between the aneurysm and the renal arteries, but not healthy between the aneurysm and the iliac arteries. The other two dilations are located in the iliac arteries between the aortic bifurcation and the bifurcations between the external iliacs and the internal iliacs. The iliac arteries are healthy between the iliac bifurcation and the aneurysms. A Type II C aneurysm also comprises three dilations. However, in a Type II C aneurysm, the dilations in the iliac arteries extend to the iliac bifurcation.

15 A Type III aneurysm is a single dilation located between the renal arteries and the iliac arteries. In a Type III aneurysm, the aorta is not healthy between the renal arteries and the aneurysm. In other words, the dilation extends to the renal arteries.

20 A ruptured abdominal aortic aneurysm is presently the thirteenth leading cause of death in the United States. The routine management of abdominal aortic aneurysms has been surgical bypass, with the placement of a graft in the involved or dilated segment. Although resection with a synthetic graft via transperitoneal or retroperitoneal procedure has been the standard treatment, it  
25 is associated with significant risk. For example, complications include perioperative myocardial ischemia, renal failure, erectile impotence, intestinal ischemia, infection, lower limb ischemia, spinal cord injury with paralysis, aorta-enteric fistula, and death. Surgical treatment of abdominal aortic aneurysms is associated with an overall mortality rate of five percent in asymptomatic patients,  
30 sixteen to nineteen percent in symptomatic patients, and is as high as fifty percent in patients with ruptured abdominal aortic aneurysms.

Disadvantages associated with conventional surgery, in addition to the high mortality rate, include an extended recovery period associated with the large surgical incision and the opening of the abdominal cavity, difficulties in suturing the graft to the aorta, the loss of the existing thrombosis to support and reinforce 5 the graft, the unsuitability of the surgery for many patients having abdominal aortic aneurysms, and the problems associated with performing the surgery on an emergency basis after the aneurysm has ruptured. Further, the typical recovery period is from one to two weeks in the hospital and a convalescence period, at home, ranging from two to three months or more, if complications 10 ensue. Since many patients having abdominal aortic aneurysms have other chronic illnesses, such as heart, lung, liver and/or kidney disease, coupled with the fact that many of these patients are older, they are less than ideal candidates for surgery.

15 The occurrence of aneurysms is not confined to the abdominal region. While abdominal aortic aneurysms are generally the most common, aneurysms in other regions of the aorta or one of its branches are possible. For example, aneurysms may occur in the thoracic aorta. As is the case with abdominal aortic aneurysms, the widely accepted approach to treating an aneurysm in the 20 thoracic aorta is surgical repair, involving replacing the aneurysmal segment with a prosthetic device. This surgery, as described above, is a major undertaking, with associated high risks and with significant mortality and morbidity.

Over the past five years, there has been a great deal of research directed 25 at developing less invasive, endovascular, i.e., catheter directed, techniques for the treatment of aneurysms, specifically abdominal aortic aneurysms. This has been facilitated by the development of vascular stents, which can and have been used in conjunction with standard or thin-wall graft material in order to create a stent-graft or endograft. The potential advantages of less invasive treatments 30 have included reduced surgical morbidity and mortality along with shorter hospital and intensive care unit stays.

Stent-grafts or endoprostheses are now Food and Drug Administration (FDA) approved and commercially available. Their delivery procedure typically involves advanced angiographic techniques performed through vascular accesses gained via surgical cut down of a remote artery, which may include the 5 common femoral or brachial arteries. Over a guidewire, the appropriate size introducer will be placed. The catheter and guidewire are passed through the aneurysm. Through the introducer, the stent-graft will be advanced to the appropriate position. Typical deployment of the stent-graft device requires withdrawal of an outer sheath while maintaining the position of the stent-graft 10 with an inner-stabilizing device. Most stent-grafts are self-expanding; however, an additional angioplasty procedure, e.g., balloon angioplasty, may be required to secure the position of the stent-graft. Following the placement of the stent-graft, standard angiographic views may be obtained.

15 Due to the large diameter of the above-described devices, typically greater than twenty French (3F=1 mm), arteriotomy closure typically requires open surgical repair. Some procedures may require additional surgical techniques, such as hypogastric artery embolization, vessel ligation, or surgical bypass in order to adequately treat the aneurysm or to maintain blood flow to 20 both lower extremities. Likewise, some procedures will require additional advanced catheter directed techniques, such as angioplasty, stent placement and embolization, in order to successfully exclude the aneurysm and efficiently manage leaks.

25 While the above-described endoprostheses represent a significant improvement over conventional surgical techniques, there is a need to improve the endoprostheses, their method of use and their applicability to varied biological conditions. Accordingly, in order to provide a safe and effective alternate means for treating aneurysms, including abdominal aortic aneurysms 30 and thoracic aortic aneurysms, a number of difficulties associated with currently known endoprostheses and their delivery systems must be overcome. One concern with the use of endoprostheses is the prevention of endo-leaks and the disruption of the normal fluid dynamics of the vasculature. Devices using any

technology should preferably be simple to position and reposition as necessary, should preferably provide an acute, fluid tight seal, and should preferably be anchored to prevent migration without interfering with normal blood flow in both the aneurysmal vessel as well as branching vessels. In addition, devices using

5 the technology should preferably be able to be anchored, sealed, and maintained in bifurcated vessels, tortuous vessels, highly angulated vessels, partially diseased vessels, calcified vessels, odd shaped vessels, short vessels, and long vessels. In order to accomplish this, the endoprostheses should preferably be highly durable, extendable and re-configurable while maintaining

10 acute and long-term fluid tight seals and anchoring positions.

The market today is populated by devices approximately 20F and greater requiring the need for a surgical cut-down approach utilizing catheters, guidewires and accessory devices which substantially eliminate the need for

15 open surgical intervention. Although, the cut-down approach significantly reduces the acute complications that often accompany open surgical intervention, the ultimate goal and the market trend, is to reduce delivery system profiles and to be able to perform the procedure of delivering an endoprostheses percutaneously, as by the Seldinger technique, which eliminates the need for a

20 cut-down procedure.

To accomplish significantly lower profiles of a delivery system, the intraluminal device will typically be crimped tighter, which tends to increase stresses on the sheath. Therefore, there is a need to find some way to minimize

25 the deployment force in order to reduce the risk of damage to the endoprostheses and/or the delivery system.

## SUMMARY OF THE INVENTION

30 The reduced deployment force delivery device of the various embodiments described herein aims to overcome the limitations associated with currently utilized devices, wherein as referred to herein proximal denotes a

direction or location towards an operator and distal denotes a direction or location away from the operator.

In accordance with one embodiment, the reduced deployment force delivery device delivers an intraluminal device to an intended vessel or anatomical passage. The delivery device comprises an inner tube having a proximal region and a distal region, wherein the distal region of the inner tube is configured to receive an intraluminal device such as a stent, stent graft or other intraluminal device. A sheath, having a proximal end and a distal end, is positioned concentrically around at least a portion of the inner tube. The distal end of the sheath comprises an inner layer at least partially covering the intraluminal device and an outer layer. A proximal end of the outer layer being connected to the distal end of the sheath and the inner layer and outer layer being connected to each other at a distal end of each and configured for relative movement therebetween. In this manner, the inner layer is peeled away from the stent, stent graft or other intraluminal device as the sheath is retracted until the inner layer is completely inverted, whereafter the remaining portion of the inner layer is retracted in conventional manner to achieve deployment of the stent, stent graft or intraluminal device.

20

In another embodiment, the reduced deployment force delivery device delivers an intraluminal device to an intended vessel or anatomical passage, whereby the delivery device comprises an inner tube having a proximal region and a distal region. The distal region of the inner tube is configured to receive an intraluminal device, such as a stent, stent graft or other intraluminal device. A sheath, having a proximal end and a distal end, is positioned concentrically around at least a portion of the inner tube. The distal end of the sheath comprises an outer layer, wherein a proximal end of the outer layer is connected to the distal end of the sheath as in the earlier described embodiment. The outer layer is likewise connected to an inner layer as in the earlier described embodiment. However, the inner layer in this instance proceeds along a portion of the stent, stent graft or intraluminal device to wrap around a proximal end of the stent, stent graft or other intraluminal device and

through the lumen of the stent, stent graft or other intraluminal device to a distal end section of the inner layer beyond the distal end of the lumen of the stent, stent graft or intraluminal device. Thereafter, the inner layer returns briefly proximally along a distal portion of the stent, stent graft or intraluminal device before proceeding to connect to a distal tip of the inner tube of the delivery device. In this manner, the proximal end of the stent, stent graft or intraluminal device can be deployed before the distal end thereof by continued retraction of the sheath.

10        In either of the embodiments described herein, a lubricious material may be provided between the inner and outer layers in order to render movement thereof easier. Likewise, the inner layer in either embodiment may taper from its proximal end to its distal end so as to become larger at its distal end, although the inner layer may also be of constant dimensions.

15

#### BRIEF DESCRIPTION OF THE DRAWINGS

20        The foregoing and other features and advantages of the invention will be apparent from the following, more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings.

25        Figure 1 is a diagrammatic representation of a conventional deployment force delivery system.

Figure 2 is a diagrammatic representation of a conventional deployment force delivery system with an intraluminal device partially deployed.

30        Figure 3 is a diagrammatic representation of an alternate embodiment of a low deployment force delivery system in accordance with the invention.

Figure 4 is a diagrammatic representation of the alternate embodiment of the deployment force delivery system of Fig. 3 with the intraluminal device partially deployed in accordance with the invention.

5 Figure 5 is a diagrammatic representation of another alternate low deployment force delivery system in accordance with the invention.

10 Figure 6 is a diagrammatic representation of the alternate embodiment of the deployment force delivery system of Fig. 5 with the intraluminal device partially deployed in accordance with the invention.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

15

Various endoprostheses assemblies, which include expandable stents and/or stent grafts, have been proposed or developed for use in association with angioplasty treatments and other medical procedures such as aneurysm repair. The endoprostheses assembly is generally routed via catheter to a 20 treatment site and the stent and/or stent graft is expanded to restore the smooth patency of an anatomical passageway by opening up a blockage or narrowing, or, in the case of a grafted stent, to exclude blood flow to an opening or aneurysm such as in blood vessel or bile duct. A stent is typically cylindrical in shape comprising an expandable open frame. The stent and/or 25 stent graft will typically expand either by itself (self-expanding stents) or will expand upon exertion of an outwardly directed radial force on an inner surface of the stent frame by a balloon catheter or the like. The deployment of a stent or stent graft is substantially the same as is described in detail subsequently.

30

Accordingly, there is a need for a self-expanding stent, stent graft or intraluminal device delivery system that is able to navigate tortuous passageways, that prevents the stent, stent graft or intraluminal device from

becoming embedded therein, and that allows the physician to more easily and accurately deploy the stent, stent graft or intraluminal device within the target area.

5       Stents, for example, for endovascular implantation into a blood vessel or the like, to maintain or restore the patency of the passageway, have often been deployed percutaneously to minimize the invasiveness associated with surgical exposure of the treatment site during coronary artery bypass. 10      Percutaneous deployment is initiated by an incision into the vascular system of the patient, typically into the femoral artery. A tubular or sheath portion of an introducer is inserted through the incision and extends into the artery. The introducer has a central lumen which provides a passageway through the patient's skin and artery wall into the interior of the artery. An outwardly tapered hub portion of the introducer remains outside the patient's body to 15      prevent blood from leaking out of the artery along the outside of the sheath. The introducer lumen includes a valve to block blood flow out of the artery through the introducer passageway. A distal end of a guide wire is passed through the introducer passageway into the patient's vasculature. The guide wire is threaded through the vasculature until the inserted distal end extends 20      just beyond the treatment site. The proximal end of the guide wire extends outside the introducer.

25       For endovascular deployment, a stent, in an unexpanded or constricted configuration, is crimped onto a deflated balloon portion of a balloon catheter. The balloon portion is normally disposed near a distal end of the balloon catheter. The catheter has a central lumen extending its entire length. The distal end of the balloon catheter is threaded onto the proximal end of the guide wire. The distal end of the catheter is inserted into the introducer lumen and the catheter is pushed along the guide wire until the 30      stent reaches the treatment site. At the treatment site, the balloon is inflated causing the stent to radially expand and assume an expanded configuration. When the stent is used to reinforce a portion of the blood vessel wall, the stent is expanded such that its outer diameter is approximately ten percent to

twenty percent larger than the inner diameter of the blood vessel at the treatment site, effectively causing an interference fit between the stent and the blood vessel that inhibits migration of the stent. The balloon is deflated and the balloon catheter is withdrawn from the patient's body. The guide 5 wire is similarly removed. Finally, the introducer is removed from the artery.

An example of a commonly used stent is given in U.S. Patent Number 4,733,665 filed by Palmaz on November 7, 1985. Such stents are often referred to as balloon expandable stents. Typically the stent is made from a 10 solid tube of stainless steel. Thereafter, a series of cuts are made in the wall of the stent. The stent has a first smaller diameter which permits the stent to be delivered through the human vasculature by being crimped onto a balloon catheter. The stent also has a second or expanded diameter. The expanded diameter is achieved through the application, by the balloon catheter positioned 15 in the interior of the tubular shaped member, of a radially outwardly directed force.

However, such "balloon expandable" stents are often impractical for use in some vessels such as superficial arteries, like the carotid artery. The carotid 20 artery is easily accessible from the exterior of the human body. A patient having a balloon expandable stent made from stainless steel or the like, placed in their carotid artery might be susceptible to sever injury through day to day activity. A sufficient force placed on the patient's neck, such as by falling, could cause the stent to collapse, resulting in injury to the patient. In order to 25 prevent this, self-expanding stents have been proposed for use in such vessels. Self-expanding stents act similarly to springs and will recover to their expanded or implanted configuration after being crushed.

One type of self-expanding stent is disclosed in U.S. Patent Number 30 4,665,771. The disclosed stent has a radially and axially flexible, elastic tubular body with a predetermined diameter that is variable under axial movement of ends of the body relative to each other and which is composed of a plurality of individually rigid but flexible and elastic thread elements defining a radially self-

expanding helix. This type of stent is known in the art as a "braided stent" and is so designated herein. Placement of such stents in a body vessel can be achieved by a device which comprises an outer catheter for holding the stent at its distal end, and an inner piston which pushes the stent forward once it is in 5 position.

Other types of self-expanding stents use alloys such as Nitinol (Ni-Ti alloy), which have shape memory and/or superelastic characteristics in medical devices which are designed to be inserted into a patient's body. The shape 10 memory characteristics allow the devices to be deformed to facilitate their insertion into a body lumen or cavity and then be heated within the body so that the device returns to its original shape. Superelastic characteristics on the other hand generally allow the metal to be deformed and restrained in the deformed condition to facilitate the insertion of the medical device containing 15 the metal into a patient's body, with such deformation causing the phase transformation. Once within the body lumen the restraint on the superelastic member can be removed, thereby reducing the stress therein so that the superelastic member can return to its original un-deformed shape by the transformation back to the original phase.

20

Alloys having shape memory/superelastic characteristics generally have at least two phases. These phases are a martensite phase, which has a relatively low tensile strength and which is stable at relatively low temperatures, and an austenite phase, which has a relatively high tensile strength and which 25 is stable at temperatures higher than the martensite phase.

When stress is applied to a specimen of a metal, such as Nitinol, exhibiting superelastic characteristics at a temperature above which the austenite is stable (i.e. the temperature at which the transformation of 30 martensite phase to the austenite phase is complete), the specimen deforms elastically until it reaches a particular stress level where the alloy then undergoes a stress-induced phase transformation from the austenite phase to the martensite phase. As the phase transformation proceeds, the alloy

undergoes significant increases in strain but with little or no corresponding increases in stress. The strain increases while the stress remains essentially constant until the transformation of the austenite phase to the martensite phase is complete. Thereafter, further increase in stress is necessary to cause 5 further deformation. The martensitic metal first deforms elastically upon the application of additional stress and then plastically with permanent residual deformation.

If the load on the specimen is removed before any permanent 10 deformation has occurred, the martensitic specimen will elastically recover and transform back to the austenite phase. The reduction in stress first causes a decrease in strain. As stress reduction reaches the level at which the martensite phase transforms back into the austenite phase, the stress level in the specimen will remain essentially constant (but substantially less than the 15 constant stress level at which the austenite transforms to the martensite) until the transformation back to the austenite phase is complete, i.e. there is significant recovery in strain with only negligible corresponding stress reduction. After the transformation back to austenite is complete, further stress reduction results in elastic strain reduction. This ability to incur significant 20 strain at relatively constant stress upon the application of a load and to recover from the deformation upon the removal of the load is commonly referred to as superelasticity or pseudoelasticity. It is this property of the material which makes it useful in manufacturing tube cut self-expanding stents. The prior art makes reference to the use of metal alloys having superelastic characteristics 25 in medical devices which are intended to be inserted or otherwise used within a patient's body. See for example, U.S. Patent Number 4,665,905 to Jervis and U.S. Patent Number 4,925,445 to Sakamoto et al.

Designing delivery systems for delivering self-expanding stents has 30 proven difficult. One example of a prior art self-expanding stent delivery system is shown in U.S. Patent Number 4,580,568 to Gianturco. This patent discloses a delivery apparatus which uses a hollow sheath, like a catheter. The sheath is inserted into a body vessel and navigated therethrough so that

its distal end is adjacent the target site. The stent is then compressed to a smaller diameter and loaded into the sheath at the sheath's proximal end. A cylindrical flat end pusher, having a diameter almost equal to the inside diameter of the sheath is inserted into the sheath behind the stent. The pusher 5 is then used to push the stent from the proximal end of the sheath to the distal end of the sheath. Once the stent is at the distal end of the sheath, the sheath is pulled back, while the pusher remains stationary, thereby exposing the stent and allowing it to expand within the vessel.

10        However, delivering the stent through the entire length of the catheter may cause many problems, including possible damage to a vessel or the stent during its travel. In addition, it is often difficult to design a pusher having enough flexibility to navigate through the catheter, but also enough stiffness to push the stent out of the catheter. Therefore, it was determined that pre-15 loading the stent into the distal end of the catheter, and then delivering the catheter through the vessel to the target site may be a better approach. In order to ensure proper placement of the stent within catheter, it is often preferred that the stent be pre-loaded at the manufacturing site. Except this in itself has posed some problems. Because the catheter exerts a significant 20 force on the self-expanding stent, which keeps it from expanding, the stent may tend to become embedded within the wall of the catheter. When this happens, the catheter has difficulty sliding over the stent during delivery. This situation can result in the stent becoming stuck inside the catheter, or could damage the stent during delivery.

25

Another example of a prior art self-expanding stent delivery system is given in U.S. Patent Number 4,732,152 to Wallsten et al. This patent discloses a probe or catheter having a self-expanding stent pre-loaded into its distal end. The stent is first placed within a flexible hose and compressed before it is 30 loaded into the catheter. When the stent is at the delivery site the catheter and hose are withdrawn over the stent so that it can expand within the vessel. However, withdrawing the flexible hose over the stent during expansion could also cause damage to the stent.

Accordingly, there is a need for a self-expanding stent, stent graft or intraluminal device delivery system that is able to navigate tortuous passageways, that prevents the stent, stent graft or intraluminal device from 5 becoming embedded therein, and that allows the physician to more easily and accurately deploy the stent, stent graft or intraluminal device within the target area.

Figures 1 and 2 illustrate a partial diagrammatic representation of a 10 conventional intraluminal device delivery system 10 at various stage of deployment of the intraluminal device. Fig. 1, for example, shows the system 10 is generally comprised of an inner tube 12 and an outer sheath 14. The inner tube 12 includes a guidewire lumen through which a guidewire (not shown) is deployed to navigate to a target site. A stent, or other intraluminal 15 device, is positioned over a distal end of the inner tube 12 within the sheath 14 until the targeted site has been reached. Thereafter, as shown in Fig. 2, the sheath 14 is retracted to deploy the stent, or other intraluminal device. In Fig. 2, the stent, or other intraluminal device, 20 is shown as partially deployed, for example. Once the stent, or other intraluminal device, 20 is fully deployed 20 distally to proximally by the continued retraction of the sheath, the components comprising the delivery system 10 are retracted.

Referring to Figures 3 and 4, there is illustrated an alternate embodiment of a delivery device in accordance with the invention. For ease of 25 explanation, only the distal region of the device is illustrated as the proximal region may be substantially similar to conventional delivery devices. The reduced deployment force delivery device 100 of Figures 3 and 4 comprises an inner tube or shaft 102 and an outer sheath 104. The inner tube or shaft 102 includes a guidewire lumen. A stent, stent graft or other intraluminal device 30 200 is positioned over the distal end of the inner tube or shaft 102 and held in position by at least a portion of the inner layer 106, the outer layer 108, the outer sheath 104, or some combination thereof. The distal end of the outer sheath 104 is connected to a proximal end of an outer layer 108, which in turn

connects at its distal end to an inner layer 106 via a connector 110. In this embodiment, the connector 110 is simply a folded region between the inner and outer layers 106, 108. However, the connector 110 may comprise any suitable device for allowing relative movement between the inner and outer layers 106, 108 as described in detail subsequently. The connector 110 may be a bonded region, for example, that connects the inner layer 106 and the outer layer 108 comprised of similar or dissimilar materials. Alternatively, the outer sheath 104 could extend distally so as to comprise the outer layer and connect to the inner layer 106 via the connector 110. The inner tube or shaft 102 and the outer sheath 104 may comprise any suitable, biocompatible materials utilized in delivery catheters. For example, the inner shaft 102 may comprise high density polyethylene and the outer sheath 104 may comprise braided Nylon™. The inner and outer layers may comprise any suitable material, and preferably comprise a very supple but strong material such as woven Dacron™, woven Dyneema HDPE, ePTFE, or some combination thereof. However, as the artisan will readily appreciate, the inner and outer layers may comprise materials other than those specifically identified herein. A lubricious material may be provided between the inner layer and the outer layer to aid relative movement therebetween. The inner layer may be a constant dimension or may taper distally to a larger dimension at its distal end.

In operation, the physician retracts the outer sheath 104 to deploy the stent, stent graft or intraluminal device 200. Upon retraction of the outer sheath 104, the sheath 104 pulls the outer layer 108 which then inverts the inner layer 106 to expose the stent, stent graft or intraluminal device 200. As illustrated in Figure 4, once the inner layer 106 is completely inverted, the remaining portion of the stent, stent graft or intraluminal device 200 is deployed in the usual fashion.

Figures 5 and 6 illustrate another alternate embodiment of a reduced deployment force delivery device 300 that allows for the most distal portion of the stent, stent graft or intraluminal device 200 to be deployed last, as may be the case for an abdominal aortic aneurysm repair stent graft device that

comprises distal barbs. In this embodiment, a proximal end of a first outer layer 108 is connected to the distal end of the sheath 104 and a distal end of the first outer layer 108 is connected to the inner layer 106 as before. In this embodiment however, the inner layer 106 further proceeds to wrap around a 5 proximal end of the stent, stent graft or intraluminal device 200 and through the lumen thereof to a distal end section 107 of the inner layer 106. The distal end section 107 of the inner layer 106 then proceeds proximally along a distal portion of the stent, stent graft or intraluminal device 200, becoming a second outer layer 109, before attaching to the distal tip 112 of the inner tube 102. In 10 this manner, the stent, stent graft or intraluminal device 200 is deployed by retracting the first outer layer 108, followed by retraction of the inner layer 106 and its distal end section 107, the second outer layer 109, and continued retraction of the sheath 104. That is, until the distal end section 107 of the inner layer 106 is uncurled, as by continuous retraction of the sheath 104, the 15 distal end of the stent or stent graft remains unexpanded as illustrated in Figure 6. Of course, the outer sheath 104 could comprise the first outer layer portion and connect to the inner layer 106 via the connector 110.

In each of these embodiments, the inner layer may be constant, may 20 taper distally so as to be larger at its proximal end than at its distal end, or may taper variably between its proximal and distal ends, whereby the tapering may allow smoother and easier deployment of the stent, stent graft or intraluminal device. In addition, at least one of the inner and outer layers may be coated with a lubricious material to enhance deployment of the stent, stent graft or 25 intraluminal device as well. Further, the inner layer and the outer layer of each embodiment may be comprised of similar materials as identified herein, although the artisan will readily appreciate that other materials of similar qualities and characteristics may also be used other than those identified herein.

30

Although shown and described is what is believed to be the most practical and preferred embodiments, it is apparent that departures from specific designs and methods described and shown will suggest themselves to

those skilled in the art and may be used without departing from the spirit and scope of the invention. The present invention is not restricted to the particular constructions described and illustrated, but should be construed to cohere with all modifications that may fall within the scope for the appended claims.

## WHAT IS CLAIMED IS:

1. A reduced deployment force delivery device for intraluminal devices comprising:
  - 5 an inner tube having a proximal region and a distal region, the distal region being configured to receive an intraluminal device; and
  - 10 a sheath having a proximal end and a distal end positioned concentrically around at least a portion of the inner tube, the distal end comprising an outer layer in turn connected to an inner layer at least partially covering the intraluminal device, a proximal end of the outer layer being connected at the distal end of the sheath, whereby relative movement therebetween the inner layer and the outer layer deploys the intraluminal device.
- 15 2. The reduced deployment force delivery apparatus of claim 1, further comprising a lubricious coating between the inner layer and the outer layer.
- 20 3. The reduced deployment force delivery apparatus of claim 1, wherein the inner layer tapers from its proximal end to its distal end so as to be larger at its proximal end.
- 25 4. The reduced deployment force delivery apparatus of claim 1, wherein the inner layer and the outer layer are comprised of woven Dacron.
- 30 5. The reduced deployment force delivery apparatus of claim 1, wherein the inner layer and the outer layer are comprised of woven Dyneema HDPE.
6. The reduced deployment force delivery apparatus of claim 1, wherein the inner layer and the outer layer are comprised of ePTFE.

7. The reduced deployment force delivery apparatus of claim 1, wherein the inner layer and the outer layer are comprised of a combination of woven Dacron and woven Dyneema.

5 8. The reduced deployment force delivery apparatus of claim 1, wherein the inner layer and the outer layer are connected by a folded region therebetween.

10 9. The reduced deployment force delivery apparatus of claim 1, wherein the inner layer and the outer layer are connected by a bonded region therebetween.

15 10. The reduced deployment force delivery apparatus of claim 1, wherein the outer sheath extends distally to comprise the outer layer and connects to the inner layer via a connector.

11. A reduced deployment force delivery device for intraluminal devices comprising:

20 an inner tube having a proximal region and a distal region, the distal region configured to receive an intraluminal device having a lumen therethrough;

25 a sheath having a proximal end and a distal end; a first outer layer having a proximal end and a distal end, the proximal end of the first outer layer connected to a distal end of the sheath;

30 a second outer layer having a proximal end and a distal end; and an inner layer connected to a distal end of the first outer layer proceeding through the lumen of the intraluminal device to a distal end section of the inner layer, the distal end section of the inner layer further proceeding to become the second outer layer, a distal end of which attaches to the distal region of the inner tube.

12. The reduced deployment force delivery device of claim 11, further comprising a lubricious coating between the inner layer and the first outer layer portion and between the distal end section of the inner layer and the second outer layer portion.

5

13. The reduced deployment force delivery device of claim 11, wherein the inner layer tapers so as to be larger at its proximal end.

10

14. The reduced deployment force delivery device of claim 11, wherein the inner layer tapers variably between its proximal and distal ends.

15

15. The reduced deployment force delivery device of claim 11, wherein the inner layer, the distal end section thereof, the first outer layer and the second outer layer are comprised of woven Dacron.

20

16. The reduced deployment force delivery device of claim 11, wherein the inner layer, the distal end section thereof, the first outer layer and the second outer layer are comprised of woven Dyneema HDPE.

25

17. The reduced deployment force delivery device of claim 11, wherein the inner layer, the distal end section thereof, the first outer layer and the second outer layer are comprised of ePTFE.

30

18. The reduced deployment force delivery device of claim 11, wherein the inner layer, the distal end section thereof, the first outer layer and the second outer layer are comprised of a combination of woven Dacron and woven Dyneema HDPE.

19. The reduced deployment force delivery device of claim 11, wherein the inner layer and the first outer layer are connected by a folded region therebetween.

20. The reduced deployment force delivery device of claim 11, wherein the inner layer and the second outer layer are connected by a folded region therebetween.

5

21. The reduced deployment force delivery device of claim 11, wherein the inner layer and the first outer layer are connected by a bonded region therebetween.

10

22. The reduced deployment force delivery device of claim 11, wherein the distal end section of the inner layer and the second outer layer are connected by a bonded region therebetween.

15

23. The reduced deployment force delivery device of claim 11, wherein the sheath extends distally to comprise the first outer layer and connects to the inner layer via a connector.





Figure 3





Figure 4

Figure 5




Figure 6

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US2005/026650

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/38084 A (SCIMED LIFE SYSTEMS, INC) 16 May 2002 (2002-05-16) page 8, line 7 - line 24; figures 1-4 page 9, line 18 - line 22 page 10, line 24 - line 27 page 11, line 23 - line 25 page 12, line 3 - page 13, line 14	1,2,6, 8-10
A	----- US 2002/138127 A1 (STIGER MARK L ET AL) 26 September 2002 (2002-09-26) paragraph '0025!; figure 2 -----	3-5, 11-13, 15-17, 19-23
X	----- -/-	1,8,11, 19,20,23

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

9 November 2005

Date of mailing of the international search report

21/11/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Neumann, E

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US2005/026650

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/007192 A1 (PEDERSON GARY J ET AL) 17 January 2002 (2002-01-17)  paragraph '0022!; figure 2 paragraph '0027! -----	1,2,8, 11,12, 19,20
X	WO 01/78627 A (SCIMED LIFE SYSTEMS, INC) 25 October 2001 (2001-10-25) page 5, line 19 - page 6, line 3 page 7, line 11 - line 19; figures 4,12A-D page 11, line 21 - line 30	1,5,6,9, 10
A	-----	11,16, 17,21-23
X	US 2004/143315 A1 (BRUUN STEVEN R ET AL) 22 July 2004 (2004-07-22) paragraph '0046!; figures paragraph '0049!	1,2,6,8
A	-----	11,12, 17,19, 20,23

**INTERNATIONAL SEARCH REPORT**

 International Application No  
 PCT/US2005/026650

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0238084	A	16-05-2002	AU CA EP JP	3062002 A 2436193 A1 1333778 A2 2004531289 T	21-05-2002 16-05-2002 13-08-2003 14-10-2004
US 2002138127	A1	26-09-2002	EP JP WO	1372536 A2 2004525701 T 02076342 A2	02-01-2004 26-08-2004 03-10-2002
US 2002007192	A1	17-01-2002	AT CA DE DE EP JP WO US	276715 T 2371871 A1 60014072 D1 60014072 T2 1185218 A1 2003502108 T 0078249 A1 6280412 B1	15-10-2004 28-12-2000 28-10-2004 22-09-2005 13-03-2002 21-01-2003 28-12-2000 28-08-2001
WO 0178627	A	25-10-2001	CA EP JP US	2405386 A1 1272125 A1 2003530200 T 6702843 B1	25-10-2001 08-01-2003 14-10-2003 09-03-2004
US 2004143315	A1	22-07-2004	US	2004143272 A1	22-07-2004